Albireo: New Data in Pediatric and Adult Liver Diseases

 

• New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay^® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic parameters
• Long-term data from PEDFIC trials of Bylvay show dramatic quality of life deficits in patients and families affected by PFIC
• Studies show consistent and sustained efficacy for Bylvay across all PFIC types
• Announces new SPARK Grants Program, accepting applications for projects to improve care for rare liver diseases, starting with PFIC

https://www.biospace.com/article/releases/albireo-announces-presentation-of-new-data-in-pediatric-and-adult-liver-diseases/